Loading...
Acotec Scientific Holdings Limited
6669.HK•HKSE
Healthcare
Medical - Devices
HK$12.45
HK$0.65(5.51%)

Over the past four quarters, Acotec Scientific Holdings Limited demonstrated steady revenue growth, increasing from $115.39M in Q3 2023 to $146.17M in Q2 2024. Operating income reached $23.12M in Q2 2024, maintaining a consistent 16% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $21.25M, reflecting operational efficiency. Net income rose to $19.98M, with EPS at $0.07. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan